Navigation Links
Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
Date:3/4/2009

964 812,622 4,268,121 ------------------------------------------------------------------------- Cash used in operating activities (15,288,632) (14,422,092) (12,997,981) (88,204,848) ------------------------------------------------------------------------- INVESTING ACTIVITIES Acquisition of property and equipment (111,577) (92,221) (35,838) (813,744) Purchase of short-term investments (347,901) (949,496) (1,035,427) (49,416,864) Redemption of short-term investments 13,000,000 6,573,000 13,808,000 43,151,746 Investment in BCY LifeSciences Inc. - - - 464,602 Investment in Transition Therapeutics Inc. - - - 2,532,343 ------------------------------------------------------------------------- Cash provided by (used in) investing activities 12,540,522 5,531,283 12,736,735 (4,081,917) ------------------------------------------------------------------------- FINANCING ACTIVITIES Proceeds from exercise of stock options and warrants 41,600 51,000 241,400 15,301,068 Proceeds from private placements - - - 38,137,385 Proceeds from public offerings 3,421,309 12,063,394 - 46,278,207 ------------------------------------------------------------------------- Cash provided by financing activities 3,462,909 12,114,394 241,400 99,716,660 ------------------------------------------------------------------------- Net increase (decrease) in cash and cash equivalents during the period 714,799
'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... - Portage Biotech Inc. ("Portage") (OTC Market: PTGEF, ... Company Limited (Biohaven), announced today that dosing has ... a glutamate modulating agent. Biohaven filed an investigational ... clearance from the U.S. Food and Drug Administration ... 54% equity interest in Biohaven, a private company. ...
(Date:8/27/2015)... , Aug. 27, 2015 HUYA Bioscience ... meeting of the Japan Society of HTLV-1, held this ... Auditorium. The purpose of the Society is to promote ... the development of medical technology and research related to ... welfare. "HUYA is proud to support this ...
(Date:8/27/2015)... , Aug. 27, 2015 In response ... FedEx, UPS and The US Postal Service to ... classified as ,select agents, by the CDC, Marken ... handling these sensitive shipments. Marken uses ... regulations, trained and certified personnel to ensure the ...
(Date:8/26/2015)...  Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... for the detection of foodborne pathogens, today announced that ... & Company Emerging Growth Conference on September 2 at ... New York Marriott Marquis. A live ... investor relations section of Roka Bioscience,s website at ...
Breaking Biology Technology:Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Marken Ensures Safe Transportation Of Select Agents And Toxins 2
... hazard of CO, poisoning and advises screening of CO levels ... ... Calif., Jan. 29 Masimo (Nasdaq:,MASI), the inventor of Pulse ... that the National Association of,Emergency Medical Technicians (NAEMT) supports the ...
... schools, SANTA CRUZ, Calif., Jan. 29 ... and career resources to post-graduate and,alumni candidates, Bio ... have joined forces., On Jan. 28, Emory ... the Bio Career Center family, rounding out an,already ...
... QED International Associates, Inc,administrator for the HealthShares(TM) ... the HealthShares(TM) Exchange-Traded Funds, today announced,that effective ... January 31, 2008 KV,Pharmaceutical Company (NYSE: KV-A) ... ) in the HealthShares(TM) Composite Index. Watson,Pharmaceuticals ...
Cached Biology Technology:National Association of Emergency Medical Technicians (NAEMT) Supports Prehospital Screening for Carbon Monoxide in the Blood 2National Association of Emergency Medical Technicians (NAEMT) Supports Prehospital Screening for Carbon Monoxide in the Blood 3National Association of Emergency Medical Technicians (NAEMT) Supports Prehospital Screening for Carbon Monoxide in the Blood 4National Association of Emergency Medical Technicians (NAEMT) Supports Prehospital Screening for Carbon Monoxide in the Blood 5Online Career Site for Life Science Professionals Continues Growth 2QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Respiratory/Pulmonary Indexes 2
(Date:7/31/2015)... Den 10. internationale konference om Genomik (ICG-10, ... - 25. oktober i Shenzhen , ... i år. Siden starten i 2006 er ICB blevet ... og er en af de mest dynamiske, entusiastiske og ... nylige gennembrud og fremskridt inden for ,omik,-forskning, som yderligere ...
(Date:7/31/2015)... La 10 th International Conference on Genomics ... 22 al 25 de octubre de 2015 en ... conferencia celebra su décimo aniversario. Desde su inauguración en el ... reuniones anuales más influyentes del mundo en el campo ,ómico, ... y mejores a nivel científico. ICG-10 se ...
(Date:7/30/2015)... , July 30, 2015 Cellecta, Inc., ... gene function analysis and biomarker discovery, announced the ... Knockout Library targeting all human protein coding genes. ... "knock out" a gene,s function. Cellecta,s new Human ... throughput screening tool so that researchers can investigate ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2
... the Entomological Society of America (ESA) gave presentations at ... Solutions to the Bed Bug Problem," held by the ... 2, 2011. The meeting focused on what is ... educating consumers, improvements in prevention and control techniques, controlling ...
... of Zaragoza (UNIZAR) has studied precipitation trends in Spain,s ... The results show that precipitation has declined overall between ... of the rainy season. The rains are heavier in ... ,Since 1946, the average precipitation falling on Spanish hydrological ...
... researchers are sequencing the genomes of social insects. The most ... Proceedings of the National Academy of Sciences , come ... Pogonomyrmex barbatus . A team, lead by Arizona ... one of the genomes and set out to decipher which ...
Cached Biology News:ESA members take part in National Bed Bug Summit 2ESA members take part in National Bed Bug Summit 3Rain in Spain is on the decline 2Seeking social genes 2
E2F2 protein...
Anti-DDDDK-Tag (Enterokinase Cleavage Site), Agarose Conjugate Research Focus: tag Storage: 4C Shipping Temperature: 4C...
Goat polyclonal to XAGE1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: CGFGFRRQGEDNT, corresponding to C terminal amino acids 149-160 of Human XAGE1 Entrez Gene ID: 9...
Sheep polyclonal to Staphylococcus DNase ( Abpromise for all tested applications). Antigen: Full length native protein (purified)....
Biology Products: